EP0000750A1 - 1,2-Benzisothiazoles et procédé pour leur préparation - Google Patents
1,2-Benzisothiazoles et procédé pour leur préparation Download PDFInfo
- Publication number
- EP0000750A1 EP0000750A1 EP78100536A EP78100536A EP0000750A1 EP 0000750 A1 EP0000750 A1 EP 0000750A1 EP 78100536 A EP78100536 A EP 78100536A EP 78100536 A EP78100536 A EP 78100536A EP 0000750 A1 EP0000750 A1 EP 0000750A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- parts
- benzisothiazole
- phenyl
- chloro
- benzisothiazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
Definitions
- the invention relates to new 1,2-benzisothiazoles and a process for the preparation of 1,2-benzisothiazoles by reacting o-haloaryl ketones with ammonia and elemental sulfur.
- DOS 25 03 699 relates to a process for the preparation of 1,2-benzisothiazoles of the formula in which R 1 is hydrogen, an aliphatic, cycloaliphatic or an optionally fused aromatic residue, halogen, an alkoxy or nitro group or the rest.
- R 1 is hydrogen, an aliphatic, cycloaliphatic or an optionally fused aromatic residue, halogen, an alkoxy or nitro group or the rest.
- the individual radicals R 2 may be the same or different and each represent hydrogen, an aliphatic, cycloaliphatic, araliphatic or aromatic radical ,. designated; where o-haloaryl aldehydes of the formula in which X represents halogen and R 1 has the abovementioned meaning, reacted with ammonia and elemental sulfur.
- R 1 is hydrogen, an aliphatic, cycloaliphatic or an optionally fused aromatic residue, halogen, an alkoxy group, nitro group or the rest in which the individual radicals R 2 can be identical or different and in each case denote hydrogen, an aliphatic, cycloaliphatic, araliphatic or aromatic radical, and R3 denotes a substituted mono- nuclear or unsubstituted polynuclear or substituted polynuclear, aromatic radical or a heterocyclic radical is found.
- the reaction can be represented as follows:
- the process according to the invention starts from readily accessible starting materials and surprisingly provides 1,2-benzisothiazoles in a better yield and purity in a simple and economical manner.
- the ketones II can also be converted to 1,2-benzisothiazoles which have not been described so far and which are substituted in the 3-position by aromatic or heterocyclic radicals.
- Preferred starting materials II and correspondingly preferred 1,2-benzisothiazoles I are those in the formulas R 1 of which is an alkyl radical with up to 6 carbon atoms optionally substituted by a carbonamide group, a cycloalkyl radical with 5 to 12 carbon atoms, a phenyl or naphthyl radical, each of which also fuses can be a fused naphthoquinone- (1,4) -ylene radical, hydrogen, bromine or especially chlorine, an alkoxy group with 1 to 4 carbon atoms, a nitro group or the rest wherein the individual radicals R 2 are the same or different and each hydrogen represents an alkyl radical with 1 to 6 carbon atoms, an alkenyl radical with 3 to 6 carbon atoms, a cycloalkyl radical with 5 to 8 carbon atoms, an aralkyl radical with 7 to 12 carbon atoms, a phenyl radical, R 3 denotes an unsubstituted or a through one or more,
- radicals can also be substituted by groups which are inert under the reaction conditions, for example alkyl groups or alkoxy groups each having 1 to 4 carbon atoms, nitro groups, carbonamido groups.
- groups which are inert under the reaction conditions for example alkyl groups or alkoxy groups each having 1 to 4 carbon atoms, nitro groups, carbonamido groups.
- substances which form the starting materials II under the reaction conditions for example the corresponding aldehyde acetals such as o-chlorobenzophenone dimethylacetal.
- Starting materials II, ammonia and elemental sulfur can be used in approximately stoichiometric amounts, but a ratio of 2 to 10 moles of ammonia and / or 0.9 to 1.1 gram atom of sulfur per mole of starting material II is preferably used.
- suitable starting materials II are: 5-nitro-, 4-dimethylamino-, 4-diethylamino-, 4-diallylamino-, 4-di- (2'-methylallyl) -amino-, 4- (N-methyl-N -2-carbonamido-ethylamino) -, 6-methyl, 3-ethyl, 5-hexyl, 6-isobutyl, 5-propyl, 4-tert-butyl, 4-cyclohexyl, 4-cyclopentyl -, 5-phenyl-, 4-phenyl-, 4-nitrophenyl-, 4-p-toluyl-, 4-p-ethoxyphenyl-, 3-di- (2'-ethoxyethyl) -amino-, 4-naphthyl-, 4-bromo, 6-methoxy, 6-dicyclohexylamino, 4-dibenzylamino, 4-diphenylamino, 4-p-xylyl-2-chloro
- the reaction is generally carried out at a temperature of 20 to 250 ° C., advantageously from 20 to 200 ° C., preferably from 40 to 180 ° C., in particular from 40 to 120 ° C., without pressure or under pressure, continuously or batchwise.
- the reaction pressure is generally determined by the total vapor pressure of the components at the reaction temperature.
- organic solvents which are inert under the reaction conditions can be used, for example aromatic hydrocarbons such as toluene, Ethylbenzene, o-, m-, p-xylene, isopropylbenzene; Alkanols and cycloalkanols such as ethanol, n-butanol, isobutanol, methyl glycol, cyclohexanol, propanol, methanol, 2-ethyl hexanol; Ether, for example ethyl propyl ether, diisobutyl ether, methyl tert.
- aromatic hydrocarbons such as toluene, Ethylbenzene, o-, m-, p-xylene, isopropylbenzene
- Alkanols and cycloalkanols such as ethanol, n-butanol, isobutanol, methyl glycol, cyclohexan
- the solvent is expediently used in an amount of 200 to 10,000 percent by weight, preferably 300 to 1,000 percent by weight, based on starting material II.
- the reaction can be carried out as follows: Starting material II, elemental sulfur and ammonia, optionally in the presence of a solvent, are reacted with one another in a pressure reactor for 3 to 10 hours at the aforementioned temperature.
- the 1,2-benzisothiazole I is obtained from the reaction mixture by the usual methods, e.g. by fractional distillation, filtration and, if appropriate, subsequent recrystallization from a suitable solvent, e.g. Ligroin.
- the reaction mixture can also be poured into water after removal of excess ammonia and solvent, the mixture formed with a suitable solvent, e.g. Extract methylene chloride, benzene and work up the extract in the aforementioned manner.
- the compounds which can be prepared by the process of the invention are valuable starting materials for the production of dyes, crop protection agents and pharmaceuticals.
- the 1,2-benzisothiazoles with the preferred meanings of R 3 are advantageously suitable for the abovementioned uses.
- 1,2-benzisothiazoles of the formula L. in which R 1 has the meaning given above by reaction with a diamine of the general formula in the Y a bridge member of the formula represents, and elemental sulfur, advantageously in an inert, organic solvent, compounds of the formula in which R 1 has the abovementioned meaning, in particular a hydrogen atom, an alkyl radical having 1 to 4'C atoms, an alkoxy radical having 1 to 3 C atoms, a halogen atom or a nitro group and Y has the meaning given, and, if appropriate, the Compounds IV thus obtained can be converted into physiologically acceptable acid addition salts.
- R is a hydrogen atom, a halogen atom, especially a chlorine or bromine atom, a nitro group, an alkyl group or an alkoxy group each having 1 to 4 carbon atoms and Y 1 Methyläthylen-1,2 and trimethylene-1 To name 3. Hydrogen and R 1 -methyl-1,2 and trimethylene-1,3 are particularly preferred for R 1 .
- the aforementioned reaction of the compounds IV is advantageously carried out at temperatures from 40 to 150 ° C., preferably at temperatures from 70 to 120 ° C.
- Appropriate solvents for the reaction of the compounds IV are aromatic hydrocarbons, in particular benzene hydrocarbons, such as benzene or toluene, lower alcohols, such as methanol, ethanol, propanol, isopropanol, butanol or isobutanol, saturated cyclic or aliphatic ethers, such as dibutyl ether or dioxane, glycol ether, in particular monoalkyl ethers of glycol, such as glycol monomethyl ether or glycol monoethyl ether, or mixtures of the solvents mentioned.
- aromatic hydrocarbons in particular benzene hydrocarbons, such as benzene or toluene
- lower alcohols such as methanol, ethanol, propanol, isopropanol, butanol or isobutanol
- saturated cyclic or aliphatic ethers such as dibutyl ether or dioxane
- glycol ether in particular
- the benzene carbon. wa.sserstoffe advantageously benzene and toluene, and monoalkyl ether of glycol, especially glycol monomethyl ether, preferred.
- the diamine of the formula III calculated on the compound of the formula I or Ib, is used in stoichiometric or in excess amount, optionally up to 3 times the stoichiometric amount.
- the elemental sulfur, calculated on the compound Ib, is used in a stoichiometric or excess amount up to 1.2 times the amount above the stoichiometric amount. turns.
- the stoichiometric amount of elemental sulfur is preferably used.
- the starting compounds of the formula Ib can be obtained, for example, by side chain chlorination of 3- (4-methylphenyl) -1,2-benzisothiazole I with chlorine at about 170 ° C. and under UV radiation.
- 3- [4- (1,3-diazacycloalken-2-yl) phenyl] -1,2-benzisothiazoles IV and their physiologically tolerated acid addition salts have valuable pharmacological properties. They can be used to produce pharmaceutical preparations which, in addition to conventional pharmaceutical carriers and diluents, contain a compound of the formula IV as an active ingredient.
- 3- [4- (Tetrahydropyrimidin-2-yl) -phenyl] -1,2-benzisothiazole, 3- [4- (methylimidazolin-2-yl) -phenyl] -1,2-benzisothiazole and their physiologically tolerable are particularly suitable Acid addition salts.
- Substances IV and their physiologically compatible acid addition salts are characterized by a strong antiarrhythmic effect and are particularly suitable for the pharmacotherapy of cardiac arrhythmias.
- the substances were administered orally to rats (strain: Sprague Dawley, weight: 180-240 g) 45 minutes before the start of anesthesia (thiobutabarbital 100 mg / kg i.p.).
- Aconitin served as the arrhythmogenic substance and was infused intravenously 60 minutes after the substance application (dosage rate: 0.005 mg / kg ⁇ minute).
- dose rate 0.005 mg / kg ⁇ minute.
- the dose was determined, which prolonged the infusion duration by 50% (ED 50%).
- the known substance served as reference substance Antiarrhythmicum procainamide.
- the acute toxicity was determined in groups of 10 or 20 female Swiss mice, weight 20-26 g, with intraperitoneal application.
- the LD 50 was calculated as the dose (probit analysis) after which 50% of the animals died within 7 days.
- Table 1 shows that the compounds of Examples 2 and 3, compared to the antiarrhythmicum procainamide, are around 5 times more antiarrhythmic. Another advantage is that the effect of the maximum dose reaches 114 (example 2) or 73% (example 3) higher values than that of procainamide; i.e. that the aconitine antagonism of the tested compounds is significantly more pronounced than that of procainamide.
- the therapeutic index as the quotient of the lethal dose (LD 50) and the antiarrhythmic dose (ED 50%) is 4 times (example 2) and 2.8 times (example 3). larger than that of procainamide.
- the therapeutic agents or preparations are produced in a known manner with the usual carriers or diluents and the commonly used pharmaceutical-technical auxiliaries in accordance with the desired type of application with a suitable dosage.
- the preferred preparations are in a dosage form which is suitable for oral administration.
- dosage forms are, for example, tablets, film-coated tablets, dragees, capsules, pills, powders, solutions or suspensions or depot forms.
- parenteral forms of preparation such as injection solutions or additives to infusion solutions, can also be used.
- Suppositories may also be mentioned as preparations.
- the corresponding tables can, for example, by mixing the active ingredient with known auxiliaries, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn, starch, alginic acid or polyvinylpyrrolidone, binders such as starch or Gelatin, lubricants such as magnesium stearate or talc and / or agents to achieve the depot effect, such as carboxypolymethylene, carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate can be obtained.
- auxiliaries for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn, starch, alginic acid or polyvinylpyrroli
- coated tablets can be produced by coating cores produced analogously to the tablets with agents conventionally used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. It can also Drageehülle consist of several layers, wherein the excipients mentioned above for the tablets can be used.
- agents conventionally used in tablet coatings for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. It can also Drageehülle consist of several layers, wherein the excipients mentioned above for the tablets can be used.
- Solutions or suspensions with the active ingredients according to the invention can additionally contain taste-improving agents such as saccharin, cyclamate or sugar and, for example, flavoring agents such as vanillin or orange extract. They can also contain suspending aids such as sodium carboxymethyl cellulose or preservatives such as parahydroxybenzoates.
- Capsules containing active ingredients can be produced, for example, by mixing the active ingredient with an inert carrier, such as milk sugar or sorbitol, and encapsulating it in gelatin capsules.
- Suitable suppositories can be produced, for example, by mixing with the carrier material provided, such as neutral fats or polyethylene glycols or their derivatives.
- the single dose of a substance according to the invention in humans is 5 to 100 mg, preferably 10 to 80 mg.
- the parts given in the following examples are parts by weight. They relate to parts by volume like kilograms to liters.
- the crystals formed are suction filtered, dissolved in 300 parts of water, filtered, the filtrate with conc. NaOH made alkaline and extracted with methylene chloride.
- the methylene chloride phase is dried and 20 parts of hydrogen chloride gas are introduced. 17 parts of the desired end product are obtained as colorless crystals with a melting point of 243 ° C. The yield corresponds to 52% of theory.
- the active ingredient is moistened with polyvinylpyrrolidone in a 10 percent aqueous solution, passed through a sieve with a mesh size of 1.0 mm and dried at 50 ° C. These granules are mixed with polyethylene glycol (average M.G. 4000), hydroxypropylmethyl cellulose, talc and magnesium stearate and pressed into tablets of 280 mg each.
- the mixture of the active substance with lactose and corn starch is granulated with an 8% aqueous solution of the polyvinylpyrrolidone through a 1.5 mm sieve, dried at 50 ° C. and again passed through a 1.0 mm sieve.
- the granules thus obtained are mixed with magnesium stearate and pressed to dragee cores.
- the dragee cores obtained are coated in a conventional manner with a casing which consists essentially of sugar and talc.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2734866 | 1977-08-03 | ||
DE19772734866 DE2734866A1 (de) | 1977-08-03 | 1977-08-03 | Neue 1,2-benzisothiazole und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0000750A1 true EP0000750A1 (fr) | 1979-02-21 |
Family
ID=6015458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100536A Withdrawn EP0000750A1 (fr) | 1977-08-03 | 1978-07-28 | 1,2-Benzisothiazoles et procédé pour leur préparation |
Country Status (4)
Country | Link |
---|---|
US (1) | US4277477A (fr) |
EP (1) | EP0000750A1 (fr) |
JP (1) | JPS5436261A (fr) |
DE (1) | DE2734866A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3018108A1 (de) | 1980-05-12 | 1981-11-19 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von 1,2-benzisothhiazolen |
US4411901A (en) * | 1981-12-23 | 1983-10-25 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
CA2408396A1 (fr) | 2000-04-17 | 2001-10-25 | Basf Aktiengesellschaft | Composes de benzisoxazole et de benzisothiazole substitute en 3 positions par un heterocycle herbicides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2503699A1 (de) * | 1975-01-30 | 1976-08-05 | Basf Ag | Verfahren zur herstellung von 1,2- benzisothiazolen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682941A (en) * | 1967-03-18 | 1972-08-08 | Basf Ag | Production of 1,2-benzoisothiazoles |
DE1915387A1 (de) * | 1969-03-26 | 1970-10-01 | Basf Ag | Herbizid |
DE2609864C2 (de) * | 1976-03-10 | 1984-02-16 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von 3-Amino-1,2-benzisothiazolen |
DE2734882A1 (de) * | 1977-08-03 | 1979-02-22 | Basf Ag | 3- eckige klammer auf 4-(1,3-diazacycloalken-2-yl)-phenyl eckige klammer zu -1,2-benzisothiazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4178451A (en) * | 1978-07-13 | 1979-12-11 | E. R. Squibb & Sons, Inc. | 3-(Substituted hydrazino)benzisothiazole-1,1-dioxides |
-
1977
- 1977-08-03 DE DE19772734866 patent/DE2734866A1/de not_active Withdrawn
-
1978
- 1978-07-28 EP EP78100536A patent/EP0000750A1/fr not_active Withdrawn
- 1978-08-02 JP JP9372578A patent/JPS5436261A/ja active Pending
-
1979
- 1979-10-02 US US06/081,059 patent/US4277477A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2503699A1 (de) * | 1975-01-30 | 1976-08-05 | Basf Ag | Verfahren zur herstellung von 1,2- benzisothiazolen |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 58, (1963) 11340c, 8 Ric. Sci Rend. Ser. B2 177-8 (1962) * |
Also Published As
Publication number | Publication date |
---|---|
DE2734866A1 (de) | 1979-02-22 |
US4277477A (en) | 1981-07-07 |
JPS5436261A (en) | 1979-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT363096B (de) | Verfahren zur herstellung von neuen phthalazinderivaten und deren salzen | |
DE2205815A1 (de) | Piperazinderivate und verfahren zu ihrer herstellung | |
EP0005828B1 (fr) | Nouvelles dérivés de la phénylpipérazine substitués, médicaments les contenant et procédés pour leur préparation | |
EP0204269B1 (fr) | Dérivés de la pyridine, leur préparation et leur application | |
DE2503002A1 (de) | Substituierte piperidinderivate, ein verfahren zu ihrer herstellung sowie arzneimittel | |
EP0101574B1 (fr) | 1-aminoalkyl-1,2,3,4-tétrahydro-beta-carbolines, leur préparation et leur utilisation comme médicaments | |
DE2711655C2 (fr) | ||
EP0000220A1 (fr) | Dihydrouraciles, procédé pour leur préparation et médicaments les contenant | |
DE2712023A1 (de) | Sulfonamidoaminobenzoesaeurederivate, solche enthaltende arzneimittel sowie verfahren zur herstellung derselben | |
EP0105210B1 (fr) | Dérivés de l'isoquinoléine, leur procédé de préparation compositions pharmaceutiques les contenant et leur utilisation | |
EP0056866B1 (fr) | Dérivés phénylpipérazines d'hétarylphénoles et d'hétarylanilines, leur préparation et leurs compositions pharmaceutiques | |
EP0019172A1 (fr) | 11-Alkylène-morphantridines substituées en position 6, procédé pour leur préparation et compositions thérapeutiques les contenant | |
DE2921660A1 (de) | 5-nitroimidazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende antiprotozoen-mittel | |
DE3025238C2 (fr) | ||
DE3900028A1 (de) | Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
DE2219171A1 (de) | Substituierte Cycloalkyl-lactamimide | |
EP0000750A1 (fr) | 1,2-Benzisothiazoles et procédé pour leur préparation | |
EP0000727B1 (fr) | 3-(4-(1,3-Diazacycloalcen-2-yl)-phenyl)-1,2-benzisothiazole, procédé pour leur préparation et médicaments les contenant. | |
DE3305495A1 (de) | Piperazin- und homopiperazinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen | |
DE2425767A1 (de) | 3-alkyl-9-aminoalkyl-1,2,3,4-tetrahydrocarbazole und ihre verwendung in arzneimitteln | |
DE3874465T2 (de) | 1,2,3,4-tetrahydroisochonoline als antiarrhythmische mittel. | |
CH440292A (de) | Verfahren zur Herstellung neuer Aminopyrazole | |
EP0152556A1 (fr) | Dérivés d'aminopropanol de 2-hydroxypropiophénones substituées, procédé de préparation et agents thérapeutiques les contenant | |
DE2356005A1 (de) | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung | |
DE2164618A1 (de) | Verbindung mit antihypertensiver Wir kung und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB NL |
|
17P | Request for examination filed | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19810328 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19840630 Year of fee payment: 5 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MARKERT, JUERGEN, DR. Inventor name: KOHLER, ROLF-DIETER, DR. Inventor name: HAGEN, HELMUT, DR. |